Literature DB >> 30343177

Designing modified polybrominated diphenyl ether BDE-47, BDE-99, BDE-100, BDE-183, and BDE-209 molecules with decreased estrogenic activities using 3D-QSAR, pharmacophore models coupled with resolution V of the 210-3 fractional factorial design and molecular docking.

Zhenhua Chu1, Yu Li2.   

Abstract

A 3D-QSAR model was constructed to predict polybrominated diphenyl ether (PBDE) estrogenic activities expressed as median effective concentrations (pEC50), and resolution V of the 210-3 fractional factorial design and a pharmacophore model were used to modify the target PBDE molecules BDE-47, BDE-99, BDE-100, BDE-183, and BDE-209 to decrease the estrogenic activities. The persistent-organic-pollutant-related and flame-retardant properties of the modified molecules were evaluated. The mechanisms involved in decreasing PBDE estrogenic activities were explored through molecular docking. The 3D-QSAR model gave a cross-validated correlation coefficient (q2) of 0.682 (i.e., >0.5) and a non-cross-validated correlation coefficient (r2) of 0.980 (i.e., >0.9). Mono- and di-substitutions and hydrophobic substituent groups gave 40 modified molecules with decreased estrogenic activities, including modified BDE-47 and BDE-99 with pEC50 decreased by >10% and modified BDE-100, BDE-183, and BDE-209 with pEC50 decreased by >20%. The modified molecules had similar flame-retardancy to the unmodified molecules, and lower biotoxicities (by a maximum of 17.27%), persistences (by a maximum of 55.68%), bioconcentration (by 4.28%-23.91%), and long-range transport potentials (by 0.72%-18.47%). Docking indicated that hydrophobic interactions were the main factors affecting PBDE estrogenic activities. The results provide a theoretical basis for designing less estrogenic flame retardants than are currently available.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  3D-QSAR; Estrogenic activity; Molecular docking; Molecular modification; Polybrominated diphenyl ethers

Year:  2018        PMID: 30343177     DOI: 10.1016/j.jhazmat.2018.10.027

Source DB:  PubMed          Journal:  J Hazard Mater        ISSN: 0304-3894            Impact factor:   10.588


  6 in total

1.  Human Estrogen Receptor Alpha Antagonists, Part 3: 3-D Pharmacophore and 3-D QSAR Guided Brefeldin A Hit-to-Lead Optimization toward New Breast Cancer Suppressants.

Authors:  Nezrina Kurtanović; Nevena Tomašević; Sanja Matić; Elenora Proia; Manuela Sabatino; Lorenzo Antonini; Milan Mladenović; Rino Ragno
Journal:  Molecules       Date:  2022-04-28       Impact factor: 4.927

2.  Integration of Fuzzy Matter-Element Method and 3D-QSAR Model for Generation of Environmentally Friendly Quinolone Derivatives.

Authors:  Xixi Li; Baiyu Zhang; Wendy Huang; Cuirin Cantwell; Bing Chen
Journal:  Int J Environ Res Public Health       Date:  2020-05-06       Impact factor: 3.390

3.  Enhanced Biodegradation of Phthalic Acid Esters' Derivatives by Plasticizer-Degrading Bacteria (Burkholderia cepacia, Archaeoglobus fulgidus, Pseudomonas aeruginosa) Using a Correction 3D-QSAR Model.

Authors:  Haigang Zhang; Chengji Zhao; Hui Na
Journal:  Int J Environ Res Public Health       Date:  2020-07-23       Impact factor: 3.390

4.  Mitigating the Adverse Effects of Polychlorinated Biphenyl Derivatives on Estrogenic Activity via Molecular Modification Techniques.

Authors:  Wei He; Wenhui Zhang; Zhenhua Chu; Yu Li
Journal:  Int J Environ Res Public Health       Date:  2021-05-08       Impact factor: 3.390

5.  Molecular Modification of Fluoroquinolone-Biodegrading Enzymes Based on Molecular Docking and Homology Modelling.

Authors:  Si-Cheng Liu; Shi-Jun Sun; Peng Cui; Yi-Fan Ding
Journal:  Int J Environ Res Public Health       Date:  2019-09-13       Impact factor: 3.390

6.  Environmentally Friendly Fluoroquinolone Derivatives with Lower Plasma Protein Binding Rate Designed Using 3D-QSAR, Molecular Docking and Molecular Dynamics Simulation.

Authors:  Yilin Hou; Yuanyuan Zhao; Yu Li
Journal:  Int J Environ Res Public Health       Date:  2020-09-11       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.